It’s a breakthrough for advanced breast cancer patients with BRCA1 or BRCA2 gene mutations. The U.S. Food and Drug Administration last week approved its first treatment for advanced breast cancer caused by the inherited mutations. The drug, Lynparza (olaparib tablets), was previously approved to treat advanced ovarian cancer caused by mutations of BRCA1 or BRCA2.
University of Pennsylvania researcher and previous PBCC Research Award winner Dr. Susan Domchek co-led the study that led to the drug’s approval for breast cancer. Dr. Domchek calls the drug’s approval a significant advance for those women with triple-negative breast cancer and a BRCA mutation.